Test Directory
| Test Code | ||||||||||||||||||||||||||||||
| 1490 | ||||||||||||||||||||||||||||||
| Test Name | ||||||||||||||||||||||||||||||
| Buschke-Ollendorff Syndrome | ||||||||||||||||||||||||||||||
| CPT Codes | ||||||||||||||||||||||||||||||
| 81479 | ||||||||||||||||||||||||||||||
| Expected Turnaround Time | ||||||||||||||||||||||||||||||
| Typically 2 to 4 weeks from receipt of a sample in the laboratory. All cases involving ongoing pregnancies will be expedited. | ||||||||||||||||||||||||||||||
| Clinical Utility | ||||||||||||||||||||||||||||||
| Genetic analysis to provide a molecular diagnosis of this disorder. Recommended for individuals with a personal and/or family history of this disorder to ensure appropriate treatment and establish recurrence risk for family members. | ||||||||||||||||||||||||||||||
| Specimen and Container Info | ||||||||||||||||||||||||||||||
|
Non-Prenatal Specimens
Prenatal Specimens Either specimen type below is acceptable.
NOTE: For specimens from outside of North America, the preferred specimen type is Genomic DNA. HNL Genomics does not recommend shipping whole blood or cultured cells from any location other than the United States, Canada, or Mexico. |
||||||||||||||||||||||||||||||
| Transport Instructions | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Stability Requirements | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Causes for Rejection | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Methodology | ||||||||||||||||||||||||||||||
| Next Generation Sequencing and Copy Number Variation Analysis | ||||||||||||||||||||||||||||||
| Performing Location | ||||||||||||||||||||||||||||||
| Genomics - Snowdrift | ||||||||||||||||||||||||||||||
| Alternate Names | ||||||||||||||||||||||||||||||
| BOS; osteopoikilosis | ||||||||||||||||||||||||||||||
| Description | ||||||||||||||||||||||||||||||
|
Buschke-Ollendorff syndrome (BOS; MIM 166700) or osteopoikilosis (OPK) is an autosomal dominant connective tissue disorder caused by mutations in the LEMD3 gene. BOS is characterized by multiple, nontender and firm cutaneous nevi or nodules. The cutaneous nevi may be elastin rich or collagen rich. OPK is defined as %u201Cspotted bone%u201D, consisting of multiple hyperostotic foci of old remolded bone. OPK may occur in isolation, or it can occur in combination with the elastin or collagen rich cutaneous nodules. The combination of OPK and cutaneous nodules or nevi is considered as BOS. Variable expression may occur in families. Some family members may have both skin and bone lesions while others may lack one or the other findings. LEMD3 encodes the LEM domain-containing protein 3, an integral protein of the inner nuclear membrane. This molecule is thought to antagonize bone morphogenetic protein and transforming growth factor %u2013%u03B2 signaling through interactions with Smad family proteins. LEMD3 loss of function mutations have been described in BOS and OPK. |
||||||||||||||||||||||||||||||
| Testing Schedule | ||||||||||||||||||||||||||||||
| Monday-Friday | ||||||||||||||||||||||||||||||
| Genes | ||||||||||||||||||||||||||||||
| LEMD3 | ||||||||||||||||||||||||||||||
| MIM | ||||||||||||||||||||||||||||||
| 166700 | ||||||||||||||||||||||||||||||
| Disease Group | ||||||||||||||||||||||||||||||
| Skeletal Disorders, Skin | ||||||||||||||||||||||||||||||
The American Medical Association (AMA) Current Procedural Terminology (CPT) codes published by HNL Lab Medicine are guidelines and are intended for informational purposes only. CPT coding is the exclusive responsibility of the billing entity. View the Terms.
© 2026 HNL Lab Medicine. All rights reserved.